QUICKLINKS AND VIEW OPITONS
Type 2 diabetics given once-a-week Byetta injections lose 8.4 lbs in four months
Tuesday, March 25, 2008 7:29 am Email this article
Type 2 diabetics who were injected once-a-week with with 2 mg of long-acting release Byetta lost an average of 8.4 pounds after 3.75 months (15 weeks) according to a recent study from researchers at Amylin Pharmaceuticals, the makers of the drug. Patients given a dose of 0.8 mg once a week or a placebo did not lose weight. The long-acting release formula is under development by Amylin Pharmaceuticals, Inc. in San Diego, California, USA. Blood Sugar Levels
A1C of 7% or less achieved by 36% of those given 0.8 mg per week, and 86% of those given 2 mg per week
A1C of 7% or less was achieved by 36% of patients given 0.8 mg per week, and 86% of subjects given 2 mg per week compared with 0% of subjects receiving placebo.
A1C is short for glycosylated hemoglobin A1c, a marker of blood sugar levels over time.
Side effects : Mild nausea was the most common side effect—27% vs 19% vs 15%—no vomiting
Mild nausea was the most common side effect occurring in 27 percent of those receiving 2 mg per week versus 19 percent in those receiving 0.8 mg per week, and 15 percent in those receiving an injection of placebo.
“All episodes of nausea were mild, with no reports of vomiting,” the paper notes.
Side effects : Gastroenteritis—13% vs 19% vs 0%
Gastroenteritis—an irritation of the gut—occurred in 13 percent of those receiving 2 mg per week versus 19 percent in those receiving 0.8 mg per week, and 0 percent in those receiving an injection of placebo.
Side effects : Hypoglycemia—0% vs 25% vs 0%
Hypoglycemia—abnormally low blood sugar—occurred in 0 percent of those receiving 2 mg per week versus 25 percent in those receiving 0.8 mg per week, and 0 percent in those receiving an injection of placebo. ( This does not make sense that the lower dose would cause more hypoglycemia, but that is what the paper says. I would not be surprised if the numbers are backwards. )
Side effects : No withdrawals due to side effects
“There were no withdrawals because of adverse events during exenatide LAR treatment,” the authors also noted.
Subjects : 45 people
The study involved 45 people with type 2 diabetes.
They had had diabetes for an average of 5.4 years.
60% were taking metformin
Sixty percent of patients were taking metformin.
The dose of metformin ranged from 500 to 2550 mg per day.
Kim D, Macconell L, Zhuang D, Kothare P, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007 Jun, 30(6):1487-93.
AUTHOR’S CONTACT INFORMATION
Amylin Pharmaceuticals, Inc.
San Diego, California 92121, USA
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.